- Published on
Infectious Disease And Microbiology – Endocarditis (Native Valves)
Endocarditis is an infection of the endocardial surface of the heart, most commonly involving the heart valves. It is typically caused by bacteria, though fungi and, rarely, organisms such as chlamydiae or rickettsiae may be responsible. In native valve infective endocarditis (NVIE), the mitral valve is most frequently affected, followed by the aortic valve. The tricuspid valve is more commonly involved in individuals who use intravenous drugs, while pulmonic valve involvement is rare. In some cases, multiple valves may be infected simultaneously.
The incidence of NVIE ranges from approximately 1.7 to 6.2 cases per 100,000 person-years, but is significantly higher among intravenous drug users. Risk factors include intravenous drug use, prior history of endocarditis, chronic intravascular access, implanted cardiac devices, congenital heart disease, bicuspid aortic valve, rheumatic heart disease, and degenerative valvular disease. Preventive strategies include antibiotic prophylaxis for high-risk individuals—such as those with prosthetic valves, prior endocarditis, certain congenital heart diseases, or cardiac transplant recipients with valvulopathy—especially before dental procedures involving manipulation of the gingiva or oral mucosa.
The most common causative organisms are Gram-positive bacteria, with Staphylococcus aureus now being the leading cause of NVIE. Other important pathogens include viridans group streptococci, Streptococcus bovis, enterococci, coagulase-negative staphylococci, and the HACEK group of organisms. Fungal infections account for a smaller proportion of cases. Approximately 10% of cases are culture-negative, often due to prior antibiotic use or infection with fastidious organisms such as Bartonella or Coxiella burnetii.
Clinically, NVIE presents with a wide range of symptoms resulting from valvular infection, embolic phenomena, metastatic infection, and immune complex deposition. Fever is present in over 90% of patients, along with nonspecific symptoms such as malaise, fatigue, weight loss, and chills. The modified Duke criteria are widely used for diagnosis and incorporate clinical, microbiological, and echocardiographic findings. Major criteria include positive blood cultures with typical organisms and evidence of endocardial involvement on echocardiography, while minor criteria include fever, predisposing conditions, vascular and immunologic phenomena, and less specific microbiologic evidence.
On physical examination, a new or changing heart murmur is found in the majority of patients. Other findings may include petechiae, splinter hemorrhages, Osler nodes, Janeway lesions, and Roth spots, although these are less common. A thorough examination is necessary to detect complications such as embolic events or metastatic infections.
Diagnosis requires prompt laboratory and imaging evaluation. Blood cultures are critical and should be obtained before starting antibiotics, with at least three sets drawn within the first 24 hours. Most cases can be diagnosed based on positive blood cultures. Laboratory findings often include leukocytosis, elevated inflammatory markers, and abnormalities on urinalysis such as hematuria or proteinuria. In cases of culture-negative endocarditis, serologic testing for atypical organisms may be necessary.
Echocardiography is the imaging modality of choice. Transthoracic echocardiography (TTE) is often used initially, but transesophageal echocardiography (TEE) is more sensitive and is preferred when clinical suspicion is high or when TTE results are inconclusive. Imaging may reveal vegetations, abscesses, or valvular dysfunction. Additional imaging studies may be required to evaluate for embolic complications or abscess formation in other organs.
Treatment involves prolonged intravenous bactericidal antibiotic therapy tailored to the causative organism and its antimicrobial susceptibilities. Empiric therapy is initiated based on clinical suspicion and risk factors. Common regimens include penicillin or ceftriaxone for streptococcal infections, ampicillin with gentamicin for enterococci, and nafcillin or vancomycin for Staphylococcus aureus. Therapy typically lasts several weeks to ensure eradication of infection within vegetations.
Surgical intervention is required in approximately 30–50% of cases and is considered in patients with heart failure, uncontrolled infection, large vegetations with recurrent emboli, or complications such as abscess formation. Management often requires a multidisciplinary approach involving cardiology, infectious diseases, and cardiac surgery teams.
Patients with endocarditis require hospitalization for initiation of treatment and close monitoring. Follow-up includes repeated blood cultures to confirm clearance of infection, monitoring for complications, and echocardiography to assess cardiac function after treatment. Patient education is important, particularly regarding oral hygiene and prevention of future infections.
The prognosis of NVIE depends on multiple factors, including the causative organism, patient comorbidities, and presence of complications. Mortality remains significant, with rates approaching 40% at one year. Poor prognostic factors include heart failure, infection with Staphylococcus aureus, older age, immunosuppression, and extension of infection beyond the valve. Complications include heart failure, stroke, systemic emboli, renal infarction, glomerulonephritis, mycotic aneurysms, and metastatic infections such as splenic abscess or meningitis.
Endocarditis is an infection of the endocardial surface of the heart, most commonly involving the heart valves. It is typically caused by bacteria, though fungi and, rarely, organisms such as chlamydiae or rickettsiae may be responsible. In native valve infective endocarditis (NVIE), the mitral valve is most frequently affected, followed by the aortic valve. The tricuspid valve is more commonly involved in individuals who use intravenous drugs, while pulmonic valve involvement is rare. In some cases, multiple valves may be infected simultaneously.
The incidence of NVIE ranges from approximately 1.7 to 6.2 cases per 100,000 person-years, but is significantly higher among intravenous drug users. Risk factors include intravenous drug use, prior history of endocarditis, chronic intravascular access, implanted cardiac devices, congenital heart disease, bicuspid aortic valve, rheumatic heart disease, and degenerative valvular disease. Preventive strategies include antibiotic prophylaxis for high-risk individuals—such as those with prosthetic valves, prior endocarditis, certain congenital heart diseases, or cardiac transplant recipients with valvulopathy—especially before dental procedures involving manipulation of the gingiva or oral mucosa.
The most common causative organisms are Gram-positive bacteria, with Staphylococcus aureus now being the leading cause of NVIE. Other important pathogens include viridans group streptococci, Streptococcus bovis, enterococci, coagulase-negative staphylococci, and the HACEK group of organisms. Fungal infections account for a smaller proportion of cases. Approximately 10% of cases are culture-negative, often due to prior antibiotic use or infection with fastidious organisms such as Bartonella or Coxiella burnetii.
Clinically, NVIE presents with a wide range of symptoms resulting from valvular infection, embolic phenomena, metastatic infection, and immune complex deposition. Fever is present in over 90% of patients, along with nonspecific symptoms such as malaise, fatigue, weight loss, and chills. The modified Duke criteria are widely used for diagnosis and incorporate clinical, microbiological, and echocardiographic findings. Major criteria include positive blood cultures with typical organisms and evidence of endocardial involvement on echocardiography, while minor criteria include fever, predisposing conditions, vascular and immunologic phenomena, and less specific microbiologic evidence.
On physical examination, a new or changing heart murmur is found in the majority of patients. Other findings may include petechiae, splinter hemorrhages, Osler nodes, Janeway lesions, and Roth spots, although these are less common. A thorough examination is necessary to detect complications such as embolic events or metastatic infections.
Diagnosis requires prompt laboratory and imaging evaluation. Blood cultures are critical and should be obtained before starting antibiotics, with at least three sets drawn within the first 24 hours. Most cases can be diagnosed based on positive blood cultures. Laboratory findings often include leukocytosis, elevated inflammatory markers, and abnormalities on urinalysis such as hematuria or proteinuria. In cases of culture-negative endocarditis, serologic testing for atypical organisms may be necessary.
Echocardiography is the imaging modality of choice. Transthoracic echocardiography (TTE) is often used initially, but transesophageal echocardiography (TEE) is more sensitive and is preferred when clinical suspicion is high or when TTE results are inconclusive. Imaging may reveal vegetations, abscesses, or valvular dysfunction. Additional imaging studies may be required to evaluate for embolic complications or abscess formation in other organs.
Treatment involves prolonged intravenous bactericidal antibiotic therapy tailored to the causative organism and its antimicrobial susceptibilities. Empiric therapy is initiated based on clinical suspicion and risk factors. Common regimens include penicillin or ceftriaxone for streptococcal infections, ampicillin with gentamicin for enterococci, and nafcillin or vancomycin for Staphylococcus aureus. Therapy typically lasts several weeks to ensure eradication of infection within vegetations.
Surgical intervention is required in approximately 30–50% of cases and is considered in patients with heart failure, uncontrolled infection, large vegetations with recurrent emboli, or complications such as abscess formation. Management often requires a multidisciplinary approach involving cardiology, infectious diseases, and cardiac surgery teams.
Patients with endocarditis require hospitalization for initiation of treatment and close monitoring. Follow-up includes repeated blood cultures to confirm clearance of infection, monitoring for complications, and echocardiography to assess cardiac function after treatment. Patient education is important, particularly regarding oral hygiene and prevention of future infections.
The prognosis of NVIE depends on multiple factors, including the causative organism, patient comorbidities, and presence of complications. Mortality remains significant, with rates approaching 40% at one year. Poor prognostic factors include heart failure, infection with Staphylococcus aureus, older age, immunosuppression, and extension of infection beyond the valve. Complications include heart failure, stroke, systemic emboli, renal infarction, glomerulonephritis, mycotic aneurysms, and metastatic infections such as splenic abscess or meningitis.
0 Comments
